The purpose of this guideline is to assist physicians caring for patients with neuroendocrine tumors in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT), and in defining the minimum requirements for PRRT. This guideline also makes recommendations on what minimal patient, tumor, and treatment outcome characteristics should be reported for PRRT in order to make comparisons between studies possible. It is not this guideline's aim to give specific recommendations on the use of specific radiolabeled somatostatin analogs for PRRT because different analogs are being used, and their availability depends on national law and local permissions.

Additional Metadata
Keywords 1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid, Carcinoids, GEPNET, Neuroendocrine tumors, Radiolabeled somatostatin analogues, cancer radiotherapy, clinical trial, comparative study, conference paper, drug dose comparison, drug dose escalation, human, lutetium 177, multiple cycle treatment, neuroendocrine tumor, octreother, octreotide[3 tyrosine], pentetreotide in 111, peptide, peptide receptor radionuclide therapy, practice guideline, priority journal, radioisotope, somatostatin derivative, treatment duration, treatment outcome, unclassified drug, yttrium 90
Persistent URL,
Kwekkeboom, D.J, Krenning, E.P, Lebtahi, R, Komminoth, P, Kos-Kudla, B, de Herder, W.W, … Wiedenmann, B. (2009). ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology: international journal for basic and clinical studies on neuroendocrine relationships, 90(2), 220–226. doi:10.1159/000225951